🔗 Share this article

Given that America undertakes unprecedented revisions to its immunization guidelines, a particular individual has surfaced in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning Covid shots in the global health crisis and has zeroed in on possible fatalities following Covid immunization in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Agency leaders were set to unveil sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US at odds with much of the international standard with insufficient data for benefit. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

Consolidating Power at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

The new acting director has frequently advocated for ending some pediatric shot schedules in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

So far statements, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent track record in medication creation, approval processes or management, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of the center would “understand regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and each of these must be supervised,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a major management aspect to the role, which manages in excess of 5,000 employees. “It is a enormous management job, if you do it right,” she concluded.

Official Statement and Controversial Policies

When asked about questions about Høeg’s fitness for the role and whether this selection signifies greater collaboration among agency officials on immunizations, a representative said that the “questions are based on inaccurate presumptions”.

“This background is consistent with the duties of her role,” the spokesperson said, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial one-day drug-approval program that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the agency looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of immunizations.”

Established History on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, Howard observe. She released a analysis using unverified volunteer-provided data to assess the incidence of heart inflammation after COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the new federal leadership featured changing rules for novel immunizations and ending “unnecessary” immunizations, she stated following the vote on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccinations.

“She is an all-around true believer who starts off with her preconceived notions and reverse-engineers to accommodate the evidence in a highly disingenuous, untruthful manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|